Morphea in adults and children cohort III: Nested case-control study - The clinical significance of autoantibodies in morphea

JAMA Dermatology

Volumn 149, Issue 10, 2013, Pages 1159-1165

  Warner Dharamsi, Jennifer ^a   Victor, Sandra ^a   Aguwa, Nancy ^b   Ahn, Chul ^c   Arnett, Frank ^d   Mayes, Maureen D ^d   Jacobe, Heidi ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; ENZYME ANTIBODY; HISTONE ANTIBODY; LA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RNA POLYMERASE 3 ANTIBODY; RO ANTIBODY; SCL 70 ANTIBODY; SINGLE STRANDED DEOXYRIBONUCLEIC ACID ANTIBODY; SM ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BODY SURFACE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; BODY SURFACE AREA; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; DNA, SINGLE-STRANDED; FEMALE; HISTONES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; SCLERODERMA, LOCALIZED; SEVERITY OF ILLNESS INDEX;

EID: 84885907630     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.4207     Document Type: Article

References (21)

1. Zulian F, Athreya BH, Laxer R, et al; Juvenile SclerodermaWorking Group of the Pediatric Rheumatology European Society (PRES). Juvenile localized scleroderma: clinical and epidemiological features in 750 children: an international study. Rheumatology (Oxford). 2006;45(5): 614-620.
2. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5): 545-550.
3. Martini G, Murray KJ, Howell KJ, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford). 2002;41(10): 1178-1182.
4. Li SC, LieblingMS, Haines KA. Ultrasonography is a sensitive tool for monitoring localized scleroderma. Rheumatology (Oxford). 2007;46(8): 1316-1319.
5. Arkachaisri T, Fertig N, Pino S, Medsger TA Jr. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma: a single-center study. J Rheumatol. 2008;35(12): 2439-2444.
6. Falanga V, Medsger TA Jr, Reichlin M. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol. 1987;123(3): 350-353.
7. Sato S, FujimotoM, Ihn H, Kikuchi K, Takehara K. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J AmAcad Dermatol. 1994;31(4): 567-571.
8. Kim A, Marinkovich N, Jacobe H. Clinical features of generalized morphea patients with the pansclerotic subtype: a prospective study from the Morphea in Adults and Children (MAC) cohort. Presented as a poster at: Annual Meeting of the Rheumatologic Dermatology Society (RDS); November 10, 2012;Washington, DC.
9. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6): 606-613.
10. JohnsonW, Jacobe H. Morphea in Adults and Children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment. J AmAcad Dermatol. 2012;67(5): 881-889.
11. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998;25(1): 84-88.
12. Arkachaisri T, Vilaiyuk S, Li S, et al Localized Scleroderma Clinical and Ultrasound Study Group. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36(12): 2819-2829.
13. Arora-Singh RK, Assassi S, del Junco DJ, et al. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J Autoimmun. 2010;35(1): 52-57.
14. Falanga V, Medsger TA Jr, Reichlin M. High titers of antibodies to single-stranded DNA in linear scleroderma. Arch Dermatol. 1985;121(3): 345-347.
15. Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma: clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med. 1986;104(6): 849-857.
16. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIα autoantibodies in localized scleroderma. Arthritis Rheum. 2004;50(1): 227-232.
17. Kikuchi K, Takehara K, Ishibashi Y. Antinuclear antibodies in localized scleroderma: unique staining in chromosome spreads. J AmAcad Dermatol. 1989;21(6): 1301-1303.
18. Rosenberg AM, Uziel Y, Krafchik BR, et al. Antinuclear antibodies in children with localized scleroderma. J Rheumatol. 1995;22(12): 2337-2343.
19. Ruffatti A, Peserico A, Rondinone R, et al. Prevalence and characteristics of anti-single-stranded DNA antibodies in localized scleroderma: comparison with systemic lupus erythematosus. Arch Dermatol. 1991;127(8): 1180-1183.
20. Sato S, Ihn H, Soma Y, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum. 1993;36(8): 1137-1141.
21. Sato S, KoderaM, Hasegawa M, FujimotoM, Takehara K. Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol. 2004;151(6): 1182-1188.